Electra Amasses $350M in Biotech’s Latest Big IPO

Immunology Drugmaker Electra Raises $350 Million in Upsized IPO

Electra Therapeutics Announces Pricing of Upsized $350.0 Million Initial Public Offering

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics, Inc., a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer, today announced the pricing of…

Electra amasses $350M in biotech’s latest big IPO

Nearly a dozen biotechnology firms have matched or raised more than $300 million in their initial public offerings in 2026, a figure not seen since new stock sales peaked in 2021, according to BioPharma Dive data.

Electra Therapeutics Announces Upsized $350 Million IPO // Cooley // Global Law Firm

Electra's $350M IPO will help it become a commercial biotech

Electra Therapeutics became the 21st biotech of 2026 to go through with an IPO after pricing its $350 million Nasdaq debut on Thursday evening. The Bay Area biotech will use the ...